TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Geoffrey R. Oxnard, Myung‐Ju Ahn, Kōichi Goto et al.|Annals of Oncology|2020

Cited by 443